Patricia N. Hurter

Dr. Patricia Hurter serves as Chief Executive Officer of Lyndra Therapeutics, a privately held biotechnology company focused on the development of oral, ultra-long-acting, sustained-release therapies, beginning in September 2019. From 2011 to 2019 she served as Senior Vice President of Pharmaceutical and Preclinical Sciences at Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) during which time her responsibilities grew to include all CMC and preclinical development activities of Vertex’s R&D portfolio, as well as the internal GMP manufacturing facility that provides drug substance and product for clinical development and commercial supply. While serving as Interim Head of Global Regulatory Affairs from 2013-2014, she oversaw several label expansions for Kalydeco® and the submission of the new drug application for Orkambi®. She has played a leadership role in the development and commercialization of 4 transformative therapies for Vertex: Incivek®, Kalydeco®, Orkambi®, and Symdeko®. Prior to joining Vertex, Dr. Hurter was Director, Formulation Design and Characterization for Merck where she was a key member of the early development team for Januvia®, a treatment for Type II diabetes.